Included in the formulation
АТХ:D.07.X.C.01 Betamethasone in combination with other drugs
Pharmacodynamics:The drug is a combination of urea and betamethasone.
Betamethasone - glucocorticosteroid for external use; has anti-inflammatory local, anti-allergic, anti-edematous and antiproliferative effect. When exposed to the skin, the edge accumulation of neutrophils is prevented, which leads to a decrease in exudation, production of cytokines, inhibition of migration of macrophages, leading ultimately to a decrease in the processes of infiltration and granulation.
Urea has keratolytic (softening and causing rejection of the stratum corneum of the epidermis) and moisturizing effects. Urea promotes water binding and softening of the stratum corneum. In addition to keratolytic action, urea has proteolytic activity.
The drug has anti-inflammatory, anti-allergic, anti-exudative, keratolytic and antipruritic effect.
Pharmacokinetics:There is no data on the pharmacokinetics of the drug.
Indications:The drug is used to reduce the inflammatory manifestations of dry and hyperkeretic dermatoses,sensitive to external glucocorticosteroid therapy, such as: psoriasis; atopic dermatitis; eczema (atonic, childish, coin-like, pruriginous, tylotic, dishydrotic); red flat lichen; discoid lupus erythematosus; dermatitis of various etiologies (including contact dermatitis); simple chronic lichen (limited neurodermatitis); seborrheic dermatitis; diffuse neurodermatitis; itching of the skin; prurigo (prurigo).
XII.L20-L30.L20.8 Other atopic dermatitis
XII.L20-L30.L21 Seborrheic dermatitis
XII.L20-L30.L23 Allergic contact dermatitis
XII.L20-L30.L24 Simple irritant contact dermatitis
XII.L20-L30.L28.0 Simple chronic lichen
XII.L20-L30.L28.1 Scabby nodosum
XII.L20-L30.L29 Itching
XII.L20-L30.L30.0 Coin-like eczema
XII.L40-L45.L40 Psoriasis
XII.L40-L45.L43 Lichen red flat
XII.L80-L99.L93.0 Discoid lupus erythematosus
Contraindications:Child age up to 2 years; acne disease; dermatitis (perioral, toxic-allergic, herpetiform Dühring); bacterial, viral or fungal skin lesions (pyoderma, Herpes simplex, chickenpox, Herpes zoster, actinomycosis, blastomycosis, sporotrichosis); syphilis; lupus; trophic ulcers (including on the background of chronic venous and arterial insufficiency); nevus; atheroma; hemangioma; angiokeratoma; skin tumors (skin cancer, epithelioma, melanoma,xanthoma, basioma, sarcoma, Kaposi's sarcoma); Gotthron carcinoid papillomatosis of the skin; exudative erythema multiforme; pemphigus; benign pemphigus; eosinophilic fascioma; photodermatitis; neurofibromatosis; skin trauma; postvaccinal skin reactions; lactation period; hypersensitivity to any of the components of the drug.
Carefully:Care should be taken with long-term treatment, use in large areas of the skin, the use of occlusive dressings and pregnancy.
Pregnancy and lactation:Due to the fact that the safety of the use of local glucocorticosteroids in pregnant women is not established, the appointment of this group of drugs during pregnancy is justified only if the potential benefit to the mother exceeds the potential risk to the fetus.
Preparations of this class should not be used during pregnancy in large doses or for a long time.
Dosing and Administration:External means. The drug is applied a thin layer 2 times a day - in the morning and evening on the affected skin.
The use of children under the age of 12 years is possible only under medical supervision. Children aged 2 to 12 years - Apply a thin layer on a small area of the skin 1 or 2 times a day.
The duration of treatment and the amount of the drug applied depend on the type and severity of the disease, determined by the doctor.
In the treatment of children, as well as patients with facial skin lesions, the course of treatment should not exceed 5 days.
Side effects:Undesirable effects that are possible with the use of local glucocorticosteroids: burning, itching, skin irritation, dry skin, folliculitis, hypertrichosis, acne, hypopigmentation.
With prolonged use and with the use of occlusive dressings are possible: skin maceration, secondary infection, skin atrophy, striae and sweating.
If there are any side effects not described in this manual, you should consult your doctor.
Overdose:Symptoms: long-term use of local glucocorticosteroids in large doses can cause oppression of the pituitary-adrenal system, leading to secondary adrenal insufficiency and hypercorticoid phenomena, including Cushing's syndrome.
Treatment: the corresponding symptomatic treatment is indicated.Acute symptoms of hypercorticoidism are usually reversible. If necessary - correction of electrolyte imbalance. In the case of chronic toxicity, gradual elimination of glucocorticosteroids is recommended.
Interaction:There is no evidence of clinically significant drug interactions.
Special instructions:If there is skin irritation or hypersensitivity to the drug against the background of the drug, treatment should be discontinued. In case of infection, appropriate therapy should be prescribed.
Systemic absorption of glucocorticosteroids and urea with their local application will be higher when using occlusive dressings, when applied to extensive body surfaces.
Children more than adults are at risk of oppressing the function of the hypothalamic-pituitary-adrenal system due to the use of local glucocorticosteroids, due to the greater the ratio of the surface area of the body to its mass and, consequently, increased absorption of the drug.
The drug is not intended for use in ophthalmology. Avoid contact with eyes and mucous membranes.
On the skin of the face more often than on other surfaces of the body, after prolonged treatment with topical glucocorticosteroids, atrophic changes may appear. With prolonged treatment with the drug, it is recommended to cancel it gradually.